摘要
目的观察上呼吸道感染患儿临床治疗工作现状,行α干扰素与利巴韦林进行治疗,分析两种药物联合使用对于患儿免疫功能、安全性等影响。方法选取2019年1月至2019年12月期间本院收治的80例上呼吸道感染患儿,使用数字随机表法分为两组,各40例。对照组使用利巴韦林治疗,研究组使用α干扰素联合利巴韦林治疗;对比两组指标生命体征、临床症状、免疫功能及用药安全性。结果研究组体温恢复正常时间、咳嗽消失时间、鼻塞流涕消失时间、咽部充血消失时间分别为(2.1±1.2)d、(2.2±1.1)d、(2.3±1.2)d、(2.3±1.2)d,均低于对照组(2.9±1.5)d、(3.0±1.4)d、(3.1±1.3)d、(3.2±1.4)d,差异均有统计学意义(均P<0.05);治疗前,两组患者白介素-2、可溶性包细胞介素-2受体、CD4+/CD8+比值比较,差异均无统计学意义(均P>0.05);治疗后,研究组白介素-2、CD4+/CD8+比值分别为(258.4±21.7)U/ml、(1.9±0.5),均高于对照组(200.4±18.7)U/ml、(1.6±0.4),可溶性包细胞介素-2受体(267.9±40.7)U/ml,低于对照组(296.2±42.3)U/ml,差异均有统计学意义(均P<0.05);研究组不良反应发生率为5.0%,低于对照组20.0%,差异有统计学意义(P<0.05)。结论上呼吸道感染患儿使用α干扰素联合利巴韦林进行治疗,可有效改善患儿生命体征、临床症状、免疫功能,用药安全性高,该联合用药方式在临床上具有较高应用价值。
Objective To observe the status of clinical treatment for children with upper respiratory tract infection,including treatment with interferon and ribavirin,and to analyze the effects of the combination of the two drugs on the immune function and safety.Methods A total of 80 children with upper respiratory tract infection admitted to our hospital from January to December,2019 were divided into a control group and a study group.The control group were treated with ribavirin,and the study group with interferon and ribavirin.The vital signs,clinical symptoms,immune function,and drug safety were compared between the two groups.Results The time for body temperature returning to normal and times for disappearance of cough,nose congestion and running nose,pharyngeal hyperemia were shorter in the study group than in the control group[(2.1±1.2)d vs.(2.9±1.5)d,(2.2±1.1)d vs.(3.0±1.4)d,(2.3±1.2)d vs.(3.1±1.3)d,and(2.3±1.2)d vs.(3.2±1.4)d;all P<0.05].Before the treatment,there were no statistical differences in IL-2,soluble package interleukin-2 receptor,and CD4+/CD8+between the two groups(all P>0.05).After the treatment,the IL-2 level and CD4+/CD8+were higher and the soluble package interleukin-2 receptor level was lower in the study group than in the control group[(258.4±21.7)U/ml vs.(200.4±18.7)U/ml,(1.9±0.5)vs.(1.6±0.4),and(267.9±40.7)U/ml vs.(296.2±42.3)U/ml;all P<0.05].The incidence of adverse reactions was lower in the study group than in the control group(5.0%vs.20.0%;P<0.05).Conclusion Interferon and ribavirin for children with upper respiratory tract infection can effectively improve their vital signs,clinical symptoms,and immune function,and is safe,so it has high clinical application value.
作者
刘新红
Liu Xinhong(Department of Pediatrics,Dezhou Hospital of Traditional Chinese Medicine,Dezhou 253000,China)
出处
《国际医药卫生导报》
2020年第20期3095-3097,共3页
International Medicine and Health Guidance News
关键词
上呼吸道感染
患儿α干扰素
利巴韦林
免疫功能
安全性
Upper respiratory tract infection
Interferon for children
Ribavirin
Immune function
Safety
